Prometic Biotherapeutics, Inc.

Entremed, Inc.

Kedrion Biopharma Inc.

Stacy Plum

Martin Robitaille

Betty Yu

William Garzon-Rodriguez

Davida Blackman

Pierre Laurin

John W Holaday

Karen Thibaudeau

John W Madsen

William E Fogler

Carolyn F Sidor

Antonio Ruiz

Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 &#x3bc;m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.

Pharmaceutical composition comprising plasminogen and uses thereof

Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1%, and more particularly by at least 10%, of the normal plasminogen activity and for maintaining the plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-II plasminogen-deficiency or an acquired deficiency.

Plasminogen replacement therapy for plasminogen-deficiency

Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilizing agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 &#x3bc;m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.

The present invention relates a composition for treating rheumatic diseases. The composition comprises a compound having the formula wherein Ris selected from &#x2014;OCH, &#x2014;OCHCH, &#x2014;CH, &#x2014;CHCH, &#x2014;CCCH, &#x2014;CHCH&#x2014;CH, or CH&#x2014;CHCH; and one or more anti-rheumatic agents. A method of using the composition for treating rheumatic diseases in humans and animals is also disclosed.

Disease modifying anti-arthritic activity of 2-methoxyestradiol

Compositions and methods effective for eliciting an immune response for inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of a growth factor in a pharmaceutically acceptable carrier. The preferred growth factors comprise basic fibroblast growth factor and vascular endothelial growth factor. The methods involve administering to a human or animal the compositions described herein in a dosage sufficient to elicit an- immune response. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly where uncontrolled cell proliferation is influenced by the presence of growth factors. Administration of the composition to a human or animal having metastasized tumors is useful for preventing the growth or expansion of such tumors.

Growing community of inventors

Arlington, VA, United States of America

Stacy Plum